Cardiovascular risk in general is influenced by a number of risk factors and risk markers, some of them modifiable and possible to prevent, but other ones are nonmodifiable ([Table 1](#tbl1){ref-type="table"}). In subjects with a positive family history for cardiovascular disease (CVD) these risk factors or markers are often elevated as a result of genetic traits, eg, as mediated via familiar hypercholesterolemia, or socio-cultural factors, such as smoking habits, but not all of the risk is explained by conventional factors ([@b3]). There also seems to exist a special link between the risk of CVD in mothers and the corresponding risk in sons ([@b42]; [@b58]), even adjusted for conventional risk factors in the offspring ([@b42]). The causes for this association are largely unknown but could be complex. It is however well-known that a number of adverse psychosocial conditions and social stress can substantially influence the risk of CVD ([@b35]; [@b8]) and the clinical course of established disease and mortality, for example as recorded in people living in republics of the former Soviet Union ([@b47]). One hypothesis to explain some aspects of early CVD in susceptible individuals is that of ongoing early cardio-vascular aging as part of a broader process of early biological aging ([@b41]; [@b2]). This concept could be helpful not only to explain the shifting incidence and prevalence rates of CVD in societies facing varying social and socio-economic difficulties, but also offer testable hypothesis in both animal and human experiments or clinical investigations. One example of this research would be to find novel long-term markers of the biological aging process, for example telomere length and corresponding telomerase activity ([@b6]; [@b4]), even if the latter is normally highest in fetal life and early infancy -- not in adulthood.

###### 

Major modifiable and nonmodifiable risk factors for cardiovascular disease

  ------------------------------------
  **Modifiable risk factors**
  Smoking
  Physical inactivity
  Excessive alcohol consumption
  Dietary factors
  Dyslipidemia/Hyperlipidemia
  Elevated LDL -- cholesterol
  Low HDL -- cholesterol
  Elevated triglycerides
  Obesity (abdominal)
  Diabetes mellitus/hyperglycemia
  High blood pressure
  Thrombogenic factors
  Psychosocial stress
  Poor sleep and relaxation
  Adverse fetal growth pattern
  **Nonmodifiable risk factors**
  Age (chronological)
  Gender
  Ethnicity
  Medical history of CVD or diabetes
  Family history of CVD or diabetes
  ------------------------------------

What is vascular aging?
=======================

Normal vascular aging is associated with a gradual change of the vascular structure and function, resulting in decreased arterial compliance and increased arterial stiffening ([@b21]; [@b36]). This is influenced by age-dependent structural and biochemical changes, eg, in the content of elastin and collagen in the vessel wall. Superimposed on this more or less normal process is pathological arterial vascular aging (atherosclerosis) with characteristic lesions and plaque formation ([@b27]), starting with subtle increased intima media thickening (IMT) in the vessel wall ([@b10]). Another important aspect is the aging effects on impairment of endothelial-mediated vasodilatation and decrease in fibrinolysis.

In susceptible individuals the vascular aging process seems to take a more rapid course, eventually resulting in premature CVD manifestations, including coronary heart disease (CHD), myocardial infarction, stroke, and symptoms from peripheral arterial disease (PAD). Another aspect is the progressing vascular dementia with its clinical symptoms of impaired cognitive function, depression, and disturbed central regulation of physiological processes, eg, blood pressure regulation. This early (premature) vascular aging (EVA) is both influencing a more rapid course of normal age-dependent arterial changes and the superimposed pathological vascular aging based on atherosclerosis ([@b39]). The process is measurable directly by use of imaging devices such as ultrasound measurements of the arterial wall, for example in the carotid artery, the aorta, or the femoral artery, for evaluation of IMT and plaque formation. Another approach is to use physiological methods such as pulse wave velocity (PWV) or the arterial augmentation index (AI) based on pulse wave analysis, as markers of arterial stiffening. In addition the ankle-brachial pressure can be used as a marker of decreased peripheral arterial circulation. Other methods include the measurements of different biomarkers reflecting endothelial function ([@b33]), as an important part of the vascular aging process, or the measurement of telomere length ([@b55]), as outlined below. Some important features of EVA are listed in [Table 2](#tbl2){ref-type="table"}.

###### 

Features of early vascular ageing (EVA)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Increased arterial stiffness and pulse wave velocityImpaired endothelial function and vasodilatationChronic vascular inflammationIntima media thickness and early atherosclerosisHemorheological disturbances of blood flowCapillary rarefaction and dysfunctional regulationShorter telomere length/lower telomerase activityImpaired glucose and lipid metabolismInsulin resistanceOxidative stressArterial calcificationIncreased deposition of matrix substancesSmall vessel degeneration in brain and kidneyIncreased left ventricular heart (LVH) load with hypertrophy
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Telomere attrition and vascular aging
=====================================

Telomeres are specialized chromatin structures that form the end cap of the DNA helix and are shortened by each cell division until the cell can divide no more. It has been repeatedly shown that telomere length, most often measured in peripheral blood cells is shorter (reflecting so called "mitotic senescence") in subjects with arterial aging, atherosclerosis, CHD, insulin resistance, impaired glucose tolerance and type 2 diabetes, or reporting poor lifestyle habits as reflected in obesity and excessive smoking ([@b45]; [@b11]; [@b46]; [@b9]; [@b25]; [@b62]; [@b15]; [@b1]; [@b23]; [@b24]). Even psychosocial stress exposure has been shown to be associated with shorter telomere length ([@b22]), as well as with increased risk of CVD ([@b35]; [@b8]). Telomere length is even a predictor of mortality risk in subjects aged 60 years or older ([@b13]). No studies, however, have so far been able to show time-dependent changes in telomere length in relation to changes in vascular function or ultrasound imaging of arterial wall characteristics, for example the IMT, after repeated measurements. This could represent a fruitful approach in future studies of vascular changes in relation to age that is supposed to be heterogeneous in subjects at different CVD risk. Recently it was reported from the WOSCOP trial in middle-aged Scottish men that treatment with pravastatin reduced the risk of coronary heart disease associated with shorter telomeres ([@b12]).

Other molecular mechanisms associated with aging
================================================

During mitochondrial metabolic activity, reactive oxidative species (ROS) are produced and increase the oxidative stress burden. This will negatively impact on aging processes, including the potential for DNA repair function. External causes for increased ROS will add to this, by the influence of smoking and certain aspects of food processing.

Current activities to characterize the genetic background for type 2 diabetes, based on so called whole genome scan approach ([@b20]), will hopefully also shed light on the relationship with diabetes complications. Some of these complications, as influenced by hyperglycemia and other risk factors, could also be regarded as examples of early aging in poorly controlled diabetes.

In pre-hypertension and established hypertension the renin -- angiotensin system (RAS) is often activated. It has been shown that induction of angiotensin II (Ang II), one important factor in the RAS activation, also promotes a cell growth arrest with phenotypic characteristics of cell senescence, such as enlarged cell shapes, increased senescence-associated beta-galactosidase positive staining cell, and depressed cell proliferation. Apoptotic changes are increased in senescent cells. The results from one experimental study suggested that cell apoptosis is possibly an important factor in the process of pathologic and physiologic senescence of endothelial cells as well as vascular aging ([@b56]). This means that pharmacological agents blocking RAS and Ang II activity could theoretically slow down vascular aging processes.

Investigations in a population-based cohort from SWEDEN
=======================================================

One aspect of age-related changes in vascular structure is the development of IMT that can also be promoted by the influence of risk factors such as systolic blood pressure. Therefore, IMT could be a surrogate marker for structural changes in the arterial vessel wall that resembles aging effects.

In the population-based Malmö Diet Cancer -- Cardiovascular (MDC-CV) cohort study, from the city of Malmö in southern Sweden, we have access to ultrasound measurement of IMT, plaque prevalence rate, and estimation of carotid blood flow in over 6013 middle-aged men and women investigated at baseline in 1992--1995. Previous publications have reported on cross-sectional associations between the degree of IMT on the one hand with measures of insulin resistance ([@b28]) or markers of inflammation and glucose metabolism, such as adiponectin ([@b44]), on the other hand. Follow-up studies of the MDC-CV cohort have shown the predictive power of IMT for the incidence of stroke ([@b51]) and CHD ([@b52]). Increased IMT, reflecting early atherosclerosis, could also partly explain the link between low social class and low educational level with cardiovascular risk ([@b50], [@b53]). We currently do follow-up investigations after a mean duration of 14-years since the baseline investigation. Some of these subjects have, however, been treated pharmacologically for various risk factors and medical conditions in the meantime, a factor that has to be taken into account and adjusted for in all statistical analyses. One randomized controlled intervention study in a subgroup of MDC-CV showed the benefits of low-dose metoprolol for slowing of the IMT progression; the BCAPS study ([@b29]). In another randomized, controlled intervention trial the effect of the insulin sensitizing agent rosiglitazone was tested for slowing of IMT progression in subjects with type-2 diabetes or the insulin resistance syndrome ([@b30]). In summary, the MDC-CV cohort offers interesting possibilities to further elucidate on the phenomenon of early vascular aging in relation to biological, lifestyle-related, and psychosocial risk factors. Investigations of genetic markers, telomere length, and arterial stiffness (pulse wave velocity, AI) are other research options currently being explored in this cohort, similar to the ASKLEPIOS Study in Belgium ([@b48]).

The role of diabetes in early aging
===================================

The incidence of type-2 diabetes typically increases with age, due to age-related changes in beta-cell function and insulin sensitivity, in conjunction with lowered physical activity and increase in body weight and relative fat mass. Increasing levels of hyperglycemia are associated with early CVD events ([@b19]), and this could be due either to the impact of hyperglycemia *per se* or its determinants (eg, insulin resistance) or consequences (advanced glycosylation end products; AGE). The risk could, however, also be a consequence of the impact of various CVD risk factors associated with hyperglycemia (insulin resistance), eg, dyslipidemia, elevated blood pressure, defects in fibrinolysis, chronic low-grade inflammation, etc. ([@b57]). It is therefore not unexpected that subjects with type-2 diabetes mellitus also experience an elevated CVD risk, relatively more pronounced in women than in men with diabetes ([@b32]). For these well proven reasons established diabetes can be regarded as a model of early biological aging with accompanying early vascular aging that can be seen as both macro- and microvascular manifestations. In a few cases, even longstanding diabetes can however be encountered without severe complications, as described in the so-called "Golden Years Project" in the UK ([@b7]). This could be a manifestation of either protective genes for example regulation of HDL cholesterol metabolism via enzymes such as CETP, healthy lifestyle, or effects of medical care and compliance with anti-diabetes treatment, eg, insulin therapy.

The role of AGE for arterial stiffening is important, as this is a mechanisms related to the glycosylation in many various proteins in different organs, thus explaining stiffening of not only vascular tissue but also for example lung tissue in relation to the effects of hyperglycemia.

How to prevent early vascular aging?
====================================

In subjects with increased risk and a positive family history of early manifestations of CVD it is advisable to screen for and treat all conventional risk factors such as smoking, hypertension, hyperlipidemia and impaired glucose tolerance or type 2 diabetes, according to current guidelines ([@b26]). Smoking is a deleterious risk factor, not only for coronary heart disease in a dose-response fashion according to the INTERHEART study ([@b61]), but also for vascular dysfunction in general and the risk of increased insulin resistance and type 2 diabetes ([@b49]). New pharmacological treatment alternatives, for example use of the partial nicotine receptor-agonist varenicline ([@b34]), might help smokers to quit their deleterious nicotine dependence. Lifestyle improvements in general (physical exercise and a balanced diet) are also useful components for cardiovascular protection, as shown for fruit and vegetables and modest alcohol intake in the INTERHEART study. This should be applied to many people with conventional risk factors below cut-off levels in current guidelines, eg, for blood pressure, cholesterol or glucose, of increased arterial stiffness is present, being one marker of vascular aging. Other evidence-based treatment modalities include the use of ACE-inhibitors for prevention of CVD manifestations based on atherosclerosis in risk patients ([@b18]), as well as statin therapy ([@b16]), according to recent large meta-analyses. One interesting possibility is that treatment with pravastatin seems to reduce the risk for coronary heart disease events in middle-aged men with short telomeres, as described in the WOSCOP trial ([@b12]). It is still largely unproven if the angiotensin-2 (AT1) receptor blockers (ARB) can offer the same, more, or less vascular protection as compared to the more studied class of ACE-inhibitors ([@b18]). However, in the large-scale ONTARGET trial, more than 25,000 subjects with hypertension and associated risk factors have been randomized to treatment either by the ACE-inhibitor ramipril or the ARB telmisartan, or to the combination of the two drugs, for prevention of fatal and nonfatal CVD endpoints ([@b60]). This trial is of substantial clinical importance and expected to be presented in 2008.

The treatment of diabetes and its hyperglycemia should be based on a new treatment algorithm presented in 2006 by ADA and EASD ([@b40]), including a first step of lifestyle modification in combination with metformin. As an optional second step the use of insulin, sulphonylurea or glitazones can be advocated by appropriate need. How to work for a strict CVD risk factor control in all patients with diabetes is outlined in another example of new joint guidelines from the ESC/EASD in Europe ([@b54]). If all these preventive measures could be effectively applied, the risk of early (cardio-) vascular aging could be counteracted and the progression slowed in these high-risk patients.

Conclusions
===========

The concept of early (premature) vascular aging (EVA) represents a potentially fruitful model for future research into pathophysiological mechanisms behind early manifestations of CVD. For example, more research is needed to elucidate on the gene-environment interaction behind vascular and endothelial dysfunction, eg, the interaction between the genetic determinant of nitric oxide production in the endothelial wall by nitric oxide synthetase (eNOS) in relation to smoking exposure ([@b37]). We also need a more thorough evaluation of different markers of early vascular aging for CVD risk prediction: Such markers could include different measures of arterial stiffness, a hallmark of early vascular aging in combination with endothelial dysfunction as evident in some patients with hypertension ([@b59]). New biomolecular markers such as telomere length ([@b5]) have to be evaluated in various intervention studies, both with lifestyle advice and with specific drug therapy. Such potentially beneficial drugs not only include well-established drugs for vascular protection like statins and ACE-inhibitors, but also newer drugs such as ARB, the endocannaboid receptor (CB1) antagonist rimonabant, and the PPAR-activating glitazones, even if some adverse effects (heart failure) could caution against a wide use of the latter class of drugs. Examples of randomized controlled trials exploring cardiovascular protection of these newer compounds include ONTARGET for ARB ([@b60]), CRESCENDO for rimonabant ([@b17]), and RECORD for rosiglitazon ([@b31]). During 2007 the revision of guidelines for cardiovascular prevention was published ([@b26]). It is still an open question if the concept of early vascular aging will be directly addressed or not in future guidelines, but the risk factors contributing to this condition and their evidence-based treatment will certainly be. A larger question to solve is to understand and prevent many of the adverse psychosocial risk factors, and their lifestyle correlates that might speed up the process of early biological aging in general (Nilsson 2003; [@b14]). This is a question of efforts in public health policy making ([@b38]), and not a matter of drug treatment.

Finally, all physicians should educate their patients to healthy lifestyle to prevent or delay vascular aging, cardiovascular diseases, and to maintain a good quality of life and thereby increase their life expectancy.
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